Proteins > Aldo-keto reductase family 1 member B1
Page last updated: 2024-08-07 16:00:17
Aldo-keto reductase family 1 member B1
An aldo-keto reductase family 1 member B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15121]
Synonyms
EC 1.1.1.300;
EC 1.1.1.372;
EC 1.1.1.54;
Aldehyde reductase;
Aldose reductase;
AR;
1.1.1.21
Research
Bioassay Publications (63)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 5 (7.94) | 18.7374 |
| 1990's | 9 (14.29) | 18.2507 |
| 2000's | 16 (25.40) | 29.6817 |
| 2010's | 30 (47.62) | 24.3611 |
| 2020's | 3 (4.76) | 2.80 |
Compounds (110)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| fidarestat | Homo sapiens (human) | Kd | 0.0160 | 1 | 1 |
| minalrestat | Homo sapiens (human) | Kd | 0.0055 | 1 | 1 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| glyceraldehyde | Homo sapiens (human) | Km | 50.0000 | 1 | 1 |
| xylose | Homo sapiens (human) | Km | 87,000.0000 | 1 | 1 |
| retinaldehyde | Homo sapiens (human) | Km | 1,100.0000 | 1 | 1 |
| 9-cis-retinal | Homo sapiens (human) | Km | 400.0000 | 1 | 1 |
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 30, Issue:2, 2020
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.Bioorganic & medicinal chemistry, , 09-15, Volume: 27, Issue:18, 2019
An overview of benzo[b]thiophene-based medicinal chemistry.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.Bioorganic & medicinal chemistry, , 12-15, Volume: 25, Issue:24, 2017
[no title available]ACS chemical biology, , 10-21, Volume: 11, Issue:10, 2016
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.Journal of medicinal chemistry, , Mar-08, Volume: 55, Issue:5, 2012
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.Bioorganic & medicinal chemistry, , Apr-01, Volume: 18, Issue:7, 2010
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.Journal of medicinal chemistry, , Oct-06, Volume: 48, Issue:20, 2005
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.Journal of medicinal chemistry, , Jan-30, Volume: 46, Issue:3, 2003
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.Bioorganic & medicinal chemistry, , Feb-01, Volume: 20, Issue:3, 2012
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 20, Issue:19, 2010
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.Journal of medicinal chemistry, , 10-26, Volume: 60, Issue:20, 2017
[no title available]ACS chemical biology, , 10-21, Volume: 11, Issue:10, 2016
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.Bioorganic & medicinal chemistry, , Apr-01, Volume: 18, Issue:7, 2010
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.Journal of medicinal chemistry, , Jan-30, Volume: 46, Issue:3, 2003
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.Journal of medicinal chemistry, , Jun-24, Volume: 37, Issue:13, 1994
Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 19, Issue:7, 2009
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.ACS chemical biology, , 05-19, Volume: 12, Issue:5, 2017
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.Journal of medicinal chemistry, , Sep-08, Volume: 48, Issue:18, 2005
Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.Journal of medicinal chemistry, , Aug-25, Volume: 48, Issue:17, 2005
High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.Journal of medicinal chemistry, , Aug-26, Volume: 47, Issue:18, 2004
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.Journal of medicinal chemistry, , Jan-30, Volume: 46, Issue:3, 2003
A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.Journal of medicinal chemistry, , Jun-15, Volume: 43, Issue:12, 2000
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.ACS chemical biology, , 05-19, Volume: 12, Issue:5, 2017
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.Bioorganic & medicinal chemistry, , Apr-01, Volume: 18, Issue:7, 2010
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.Journal of medicinal chemistry, , Jun-24, Volume: 37, Issue:13, 1994
Synthesis and biological screening of thiosemicarbazones of substituted 3-acetylcoumarins having d-glucose moiety.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 30, Issue:24, 2020
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 30, Issue:2, 2020
Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.European journal of medicinal chemistry, , Apr-15, Volume: 168, 2019
[no title available]ACS chemical biology, , 10-21, Volume: 11, Issue:10, 2016
Pterin-7-carboxamides as a new class of aldose reductase inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 26, Issue:20, 2016
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.Bioorganic & medicinal chemistry, , Apr-01, Volume: 18, Issue:7, 2010
Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.European journal of medicinal chemistry, , Volume: 45, Issue:4, 2010
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.Journal of medicinal chemistry, , Oct-06, Volume: 48, Issue:20, 2005
Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.Journal of medicinal chemistry, , Aug-25, Volume: 48, Issue:17, 2005
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.Journal of medicinal chemistry, , Jun-15, Volume: 43, Issue:12, 2000
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors.Journal of medicinal chemistry, , May-29, Volume: 35, Issue:11, 1992
Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.Journal of medicinal chemistry, , Volume: 33, Issue:7, 1990
Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Spiro hydantoin aldose reductase inhibitors.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.Journal of medicinal chemistry, , Volume: 29, Issue:11, 1986
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.Journal of medicinal chemistry, , Volume: 28, Issue:7, 1985
Synthesis, absolute configuration, and conformation of the aldose reductase inhibitor sorbinil.Journal of medicinal chemistry, , Volume: 28, Issue:11, 1985
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 30, Issue:2, 2020
Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.European journal of medicinal chemistry, , Apr-15, Volume: 168, 2019
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 28, Issue:23-24, 2018
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 27, Issue:18, 2017
Green fluorescent protein chromophore derivatives as a new class of aldose reductase inhibitors.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Pterin-7-carboxamides as a new class of aldose reductase inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 26, Issue:20, 2016
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.Bioorganic & medicinal chemistry, , Jan-01, Volume: 20, Issue:1, 2012
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.Bioorganic & medicinal chemistry, , Apr-01, Volume: 18, Issue:7, 2010
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 20, Issue:19, 2010
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.Journal of medicinal chemistry, , Jan-30, Volume: 46, Issue:3, 2003
[no title available]ACS chemical biology, , 10-21, Volume: 11, Issue:10, 2016
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.Journal of medicinal chemistry, , Mar-12, Volume: 58, Issue:5, 2015
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis.Bioorganic chemistry, , Volume: 53, 2014
20(S)-Ginsenoside Rh2 as aldose reductase inhibitor from Panax ginseng.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 24, Issue:18, 2014
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.Bioorganic & medicinal chemistry, , Feb-01, Volume: 20, Issue:3, 2012
Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 21, Issue:4, 2011
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols.Bioorganic & medicinal chemistry, , Dec-01, Volume: 16, Issue:23, 2008
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.Journal of natural products, , Nov-25, Volume: 78, Issue:11, 2015
Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Jul-15, Volume: 21, Issue:14, 2013
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.Bioorganic & medicinal chemistry, , Feb-01, Volume: 20, Issue:3, 2012
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 21, Issue:4, 2011
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Enables
This protein enables 10 target(s):
| Target | Category | Definition |
|---|
| retinal dehydrogenase activity | molecular function | Catalysis of the reaction: retinal + NAD+ + H2O = retinoate + NADH. Acts on both 11-trans and 13-cis forms of retinal. [EC:1.2.1.36] |
| aldose reductase (NADPH) activity | molecular function | Catalysis of the reaction: an alditol + NADP+ = an aldose + NADPH + H+. [EC:1.1.1.21] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| electron transfer activity | molecular function | A molecular function representing the directed movement of electrons from one molecular entity to another, typically mediated by electron carriers or acceptors, resulting in the transfer of energy and/or the reduction-oxidation (redox) transformation of chemical species. This activity is fundamental to various biological processes, including cellular respiration and photosynthesis, as well as numerous enzymatic reactions involved in metabolic pathways. [Wikipedia:Electron_transfer] |
| prostaglandin H2 endoperoxidase reductase activity | molecular function | Catalysis of the reaction: prostaglandin H2 + NADPH + H+ -> prostaglandin F2alpha + NADP+. This reaction is the reduction of prostaglandin H2 ((5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate) to prostaglandin F2alpha ((5Z,13E)-(15S)-9alpha,11alpha,15-Trihydroxyprosta-5,13-dienoate). [GOC:mw, KEGG_REACTION:R02264, PMID:10622721, PMID:14979715, PMID:16475787] |
| glyceraldehyde oxidoreductase activity | molecular function | Catalysis of the reaction: A + D-glyceraldehyde + H2O = (R)-glycerate + AH2 + H+. [PMID:10095793, RHEA:36047] |
| allyl-alcohol dehydrogenase activity | molecular function | Catalysis of the reaction: allyl alcohol + NADP+ = acrolein + H+ + NADPH. [EC:1.1.1.54, RHEA:12168] |
| L-glucuronate reductase activity | molecular function | Catalysis of the reaction: L-gulonate + NADP+ = D-glucuronate + H+ + NADPH. [EC:1.1.1.19, RHEA:14909] |
| glycerol dehydrogenase [NADP+] activity | molecular function | Catalysis of the reaction: glycerol + NADP+ = D-glyceraldehyde + NADPH. [EC:1.1.1.72, MetaCyc:GLYCEROL-DEHYDROGENASE-NADP+-RXN] |
| all-trans-retinol dehydrogenase (NADP+) activity | molecular function | Catalysis of the reaction: all-trans-retinol + NADP+ = all-trans-retinal + NADPH + H+. [RHEA:25033] |
Located In
This protein is located in 4 target(s):
| Target | Category | Definition |
|---|
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Involved In
This protein is involved in 15 target(s):
| Target | Category | Definition |
|---|
| retinoid metabolic process | biological process | The chemical reactions and pathways involving retinoids, any member of a class of isoprenoids that contain or are derived from four prenyl groups linked head-to-tail. Retinoids include retinol and retinal and structurally similar natural derivatives or synthetic compounds, but need not have vitamin A activity. [ISBN:0198506732] |
| epithelial cell maturation | biological process | The developmental process, independent of morphogenetic (shape) change, that is required for an epithelial cell to attain its fully functional state. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface. [GOC:dph] |
| renal water homeostasis | biological process | Renal process involved in the maintenance of an internal steady state of water in the body. [GOC:mtg_cardio] |
| carbohydrate metabolic process | biological process | The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. [GOC:mah, ISBN:0198506732] |
| prostaglandin metabolic process | biological process | The chemical reactions and pathways involving prostaglandins, any of a group of biologically active metabolites which contain a cyclopentane ring due to the formation of a bond between two carbons of a fatty acid. They have a wide range of biological activities. [ISBN:0198506732] |
| C21-steroid hormone biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of C21-steroid hormones, steroid compounds containing 21 carbons which function as hormones. [GOC:ai] |
| L-ascorbic acid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of L-ascorbic acid; L-ascorbic acid ionizes to give L-ascorbate, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate, which is required as a cofactor in the oxidation of prolyl residues to hydroxyprolyl, and other reactions. [GOC:ma, ISBN:0198547684] |
| regulation of urine volume | biological process | Any process that modulates the amount of urine excreted from the body over a unit of time. [GOC:mtg_25march11, GOC:yaf] |
| retinol metabolic process | biological process | The chemical reactions and pathways involving retinol, one of the three compounds that makes up vitamin A. [GOC:jl, http://www.indstate.edu/thcme/mwking/vitamins.html, PMID:1924551] |
| negative regulation of apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
| daunorubicin metabolic process | biological process | The chemical reactions and pathways involving daunorubicin, a chemotherapeutic of the anthracycline family that is given as a treatment for some types of cancer. [PMID:20837989] |
| doxorubicin metabolic process | biological process | The chemical reactions and pathways involving doxorubicin, an anthracycline antibiotic, used in cancer chemotherapy. [PMID:10200167] |
| fructose biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of fructose, the ketohexose arabino-2-hexulose. [GOC:ai] |
| cellular hyperosmotic salinity response | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, an increase in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment. [GOC:mah] |
| metanephric collecting duct development | biological process | The process whose specific outcome is the progression of a collecting duct in the metanephros over time, from its formation to the mature structure. The collecting duct responds to vasopressin and aldosterone to regulate water, electrolyte and acid-base balance. The collecting duct is the final common path through which urine flows before entering the ureter and then emptying into the bladder. [GOC:mtg_kidney_jan10] |